Head and Neck Cancer — Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Citation(s)
Phase II Trial of Combination Weekly Bortezomib (VELCADE) and Docetaxel (TAXOTERE) in Patients With Recurrent and/ or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)